New approaches to inhibiting platelets and coagulation

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 373-397

  Depta, Jeremiah P ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Anticoagulation; Antiplatelet; Antithrombotic therapy; Atherothrombosis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APIXABAN; ATOPAXAR; CANGRELOR; CLOPIDOGREL; DABIGATRAN; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; OTAMIXABAN; PHOSPHODIESTERASE INHIBITOR; PRASUGREL; RIVAROXABAN; TICAGRELOR; TRIFLUSAL; VORAPAXAR; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; HUMAN; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; BLEEDING; BLOOD; CEREBROVASCULAR DISORDERS; CHEMICALLY INDUCED; CORONARY DISEASE; DRUG DESIGN; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATIENT SELECTION; PRIMARY PREVENTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DRUG DESIGN; HEMORRHAGE; HUMANS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 84920811343     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124438     Document Type: Review

References (130)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-128
2. Angiolillo DJ, Ferreiro JL. 2013. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Am. J. Cardiovasc. Drugs 13:233-50
3. Ruggeri ZM, Mendolicchio GL. 2007. Adhesion mechanisms in platelet function. Circ. Res. 100:1673-85
4. Depta JP, Bhatt DL. 2013. Current uses of aspirin in cardiovascular disease. Hot Topics Cardiol. 8:7-21
5. Steer. Comm. Physicians Health Study Res. Group. 1989. Final report on the aspirin component of the ongoing Physicians Health Study. N. Engl. J. Med. 321:129-35
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. 2009. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-60
7. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, et al. 2012. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e637S- 68S
8. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, et al. 2002. AHAguidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388-91
9. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, et al. 2011. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can. J. Cardiol. 27(Suppl. A):S1- 59
10. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. 2012. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33:1635-701
11. U. S. Prev. Serv. Task Force. 2009. Aspirin for the prevention of cardiovascular disease: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 150:396-404
12. Antithrombotic Trialists Collab. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
13. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, et al. 2009. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann. Intern. Med. 150:379-86
14. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, et al. 2003. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682-87
15. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. 2010. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363:930-42
16. Murdoch D, Plosker GL. 2006. Triflusal: A review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. Drugs 66:671-92
17. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. 2005. Triflusal for preventing serious vascular events in people at high risk. Stroke 37:2193-95
18. Tello-Montoliu A, Jover E, Rivera J, Valdes M, Angiolillo DJ, Marin F. 2012. New perspectives in antiplatelet therapy. Curr. Med. Chem. 19:406-27
19. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, et al. 2011. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial. Lancet 377:2013-22
20. Neri Serneri GG, Coccheri S, Marubini E, Violi F, Comm. Investig. Drug Eval. Atheroscler. Vasc. Dis. Diabet. Study Group. 2004. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur. Heart J. 25:1845-52
21. Depta JP, Bhatt DL. 2012. Antiplatelet therapy and proton pump inhibition: cause for concern? Curr. Opin. Cardiol. 27:642-50
22. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, et al. 2010. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38:92-99
23. CAPRIE Steer. Comm. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-39
24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345:494-502
25. Sabatine MS, Cannon CP, Gibson CM, L opez-Send on JL, Montalescot G, et al. 2005. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352:1179-89
26. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, et al. 2005. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607-21
27. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, et al. 2002. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288:2411-20
28. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, et al. 2006. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354:1706-17
29. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, et al. 2010. Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 376:1233-43
30. Gurbel PA, Tantry US. 2006. Drug insight: clopidogrel nonresponsiveness. Nat. Clin. Pract. Cardiovasc. Med. 3:387-95
31. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, et al. 2013. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62:2261-73
32. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, et al. 2006. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80:486-501
33. Depta JP, Bhatt DL. 2008. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am. J. Cardiovasc. Drugs 8:91-112
34. Bhatt DL. 2007. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N. Engl. J. Med. 357:2078-81
35. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, et al. 2013. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 382:614-23
36. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, et al. 2012. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308:1785-94
37. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, et al. 2011. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-105
38. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, et al. 2012. Bedsidemonitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367:2100-9
39. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, et al. 2012. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In PatientsUndergoing Elective Stent Placement on Clopidogrel to GuideAlternative TherapyWith Prasugrel) study. J. Am. Coll. Cardiol. 59:2159-64
40. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, et al. 2011. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58:e44-122
41. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, et al. 2012. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 60:645-81
42. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, et al. 2011. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32:2999-3054
43. Depta JP, Bhatt DL. 2010. Omeprazole and clopidogrel: Should clinicians be worried? Clevel. Clin. J. Med. 77:113-16
44. Shi S, Klotz U. 2008. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 64:935-51
45. Frelinger AL III, Lee RD, Mulford DJ, Wu J, Nudurupati S, et al. 2012. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J. Am. Coll. Cardiol. 59:1304-11
46. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, et al. 2010. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363:1909-17
47. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, et al. 2008. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52:1502-17
48. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, et al. 2010. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122:2619-33
49. Galper BZ, Mauri L. 2013. Antiplatelet therapy after coronary stenting. Curr. Treat. Options Cardiovasc. Med. 15:1-10
50. OGara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, et al. 2013. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61:e78-140
51. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, et al. 2010. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. Eur. Heart J. 31:2501-55
52. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, et al. 2012. ESCGuidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33:2569-619
53. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, et al. 2010. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362:1374-82
54. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, et al. 2012. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: EXCELLENT randomized, multicenter study. Circulation 125:505-13
55. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, et al. 2012. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomizedmulticenter trial. Circulation 125:2015-26
56. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, et al. 2013. Three versus twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310:2510-22
57. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, et al. 2010. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am. Heart J. 160:1035-41
58. Farid NA, Kurihara A, Wrighton SA. 2010. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50:126-42
59. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. 2007. Prasugrel: A novel thienopyridine antiplatelet agent: A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. 25:357-74
60. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357:2001-15
61. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, et al. 2009. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723-31
62. Erlinge D, ten Berg J, Foley D, Angiolillo DJ, Wagner H, et al. 2012. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J. Am. Coll. Cardiol. 60:2032-40
63. Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, et al. 2013. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J. Am. Coll. Cardiol. 62:577-83
64. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, et al. 2013. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med. 369:999-1010
65. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, et al. 2012. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367:1297-309
66. Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, et al. 2013. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 128:823-33
67. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, et al. 2013. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: A secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 382:605-13
68. Capodanno D, Dharmashankar K, Angiolillo DJ. 2010. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther. 8:151-58
69. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, et al. 2009. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577-85
70. Capodanno D, Ferreiro JL, Angiolillo DJ. 2013. Antiplatelet therapy: new pharmacological agents and changing paradigms. J. Thromb. Haemost. 11(Suppl. 1):316-29
71. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361:1045-57
72. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, et al. 2011. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124:544-54
73. US Food Drug Admin. 2011. FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes: boxed warning says daily aspirin doses above 100 milligrams decrease effectiveness. Washington, DC: US Food Drug Admin. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964. htm
74. Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, et al. 2014. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 Study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38). J. Am. Coll. Cardiol. 63:225-32
75. Montalescot G, Lassen JF, Hamm CW, Lapostolle F, Silvain J, et al. 2013. Ambulance or incatheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am. Heart J. 165:515-22
76. Ueno M, Rao SV, Angiolillo DJ. 2010. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 6:445-53
77. Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, et al. 2012. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ. Cardiovasc. Interv. 5:347-56
78. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, et al. 2012. Arandomized, double-blind, activecontrolled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ. Cardiovasc. Interv. 5:336-46
79. Ferreiro JL, Ueno M, Angiolillo DJ. 2009. Cangrelor: A review on its mechanism of action and clinical development. Expert Rev. Cardiovasc. Ther. 7:1195-201
80. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, et al. 2009. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361:2318-29
81. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, et al. 2009. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361:2330-41
82. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, et al. 2012. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am. Heart J. 163:182-90. e4
83. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, et al. 2013. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368:1303-13
84. Genereux P, Stone GW, Harrington RA, Gibson CM, Steg PG, et al. 2013. Impact of intra-procedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 63:619-29
85. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, et al. 2012. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA 307:265-74
86. Meadows TA, Bhatt DL. 2007. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 100:1261-75
87. Angiolillo DJ, Capodanno D, Goto S. 2010. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J. 31:17-28
88. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, et al. 2009. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, doubleblind, placebo-controlled phase II study. Lancet 373:919-28
89. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. 2010. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. Thromb. 17:156-64
90. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, et al. 2012. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366:20-33
91. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, et al. 2012. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366:1404-13
92. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. 2010. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31:2601-13
93. ODonoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, et al. 2011. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 123:1843-53
94. Wiviott SD, Flather MD, ODonoghue ML, Goto S, Fitzgerald DJ, et al. 2011. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the Lessons from Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial. Circulation 123:1854-63
95. Gresele P, Momi S, Falcinelli E. 2011. Anti-platelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol. 72:634-46
96. Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, OKeefe JH, et al. 2013. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am. J. Cardiol. 112:1230-34
97. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. 2006. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665-73
98. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, et al. 2008. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled study. Lancet Neurol. 7:875-84
99. ESPS Group. 1987. The European Stroke Prevention Study (ESPS): principal end-points. Lancet 330:1351-54
100. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, et al. 2008. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359:1238-51
101. Bhatt DL. 2011. Glycoprotein IIb/IIIa inhibitors:Do they still have a role? J. Am. Coll. Cardiol. 57:1200-1
102. Hanna EB, Rao SV, Manoukian SV, Saucedo JF. 2010. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. JACC Cardiovasc. Interv. 3:1209-19
103. Depta JP, Bhatt DL. 2010. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb. Haemost. 104:657-63
104. Depta JP, Cannon CP, FonarowGC, Zhao X, Peacock WF, et al. 2009. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am. J. Cardiol. 104:1171-78
105. Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, et al. 2010. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb. Haemost. 103:13-28
106. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, et al. 2013. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107-15
107. StoneGW, WitzenbichlerB, Guagliumi G, Peruga JZ, Brodie BR, et al. 2008. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358:2218-30
108. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, et al. 2009. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374:1149-59
109. Schulz S, Kastrati A, Ferenc M, Massberg S, Birkmeier KA, et al. 2013. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. Eurointervention 9:430-36
110. Steg PG, van t Hof A, Hamm CW, Clemmensen P, Lapostolle F, et al. 2013. Bivalirudin started during emergency transport for primary PCI. N. Engl. J. Med. 369:2207-17
111. Kirtane AJ, Sandhu P, Mehran R, McEntegart M, Cristea E, et al. 2014. Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). Am. J. Cardiol. 113:36-43
112. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, et al. 2014. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384:1849-58
113. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361:1139-51
114. Lip GYH, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. 2013. Patient outcomes using the European label for dabigatran: A post-hoc analysis from the RE-LY database. Thromb. Haemost. 111:933-42
115. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, et al. 2013. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 128:237-43
116. PatelMR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365:883-91
117. Bauersachs R, Berkowitz SD, Brenner B, B uller HR, Decousus H, et al. 2010. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363:2499-510
118. B uller HR, Prins MH, Lensin AWA, Decousus H, Jacobson BF, et al. 2012. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366:1287-97
119. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, et al. 2009. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 374:29-38
120. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, et al. 2012. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366:9-19
121. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, et al. 2013. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J. Am. Coll. Cardiol. 62:286-90
122. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, et al. 2013. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369:799-808
123. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365:981-92
124. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, et al. 2011. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364:806-17
125. Alexander JH, Lopes RD, James S, Kilaru R, He Y, et al. 2011. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365:699-708
126. CohenM, Bhatt DL, Alexander JH, Montalescot G, Bode C, et al. 2007. Randomized, double-blind, doseranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115:2642-51
127. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, et al. 2009. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, active-controlled, phase 2 trial. Lancet 374:787-95
128. Steg PG, Mehta SR, Pollack CV Jr, Bode C, CohenM, et al. 2013. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 310:1145-55
129. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, et al. 2006. First-in-human experience of an antidote-controlled anticoagulant usingRNAaptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114:2490-97
130. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, CohenMG, et al. 2013. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur. Heart J. 34:2481-89